Kimberlin, who previously collaborated with Dr. Jonas Salk to develop the first FDA-approved cell-based immunotherapy, ...

在细胞治疗的研究浪潮中，间充质基质细胞（MSCs）是关键的研究对象。但患者年龄及细胞获取困难等问题制约其临床应用。近日，发表在 Life Sci 的一项研究 iPSC-derived mesenchymal stromal cells ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...

Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Primary Sclerosing Cholangitis.

A Key Milestone for Therapeutic Exosome ProductionTORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- . (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...

Dec. 18, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC ...

In this study, the researchers showed that EVs from fat-derived mesenchymal stromal cells (ASC-EVs) decreased the harmful effects of senescent cells. ASC-EVs showed strong therapeutic effects in ...

New research reveals that ER+ breast cancer cells acquire aggressive characteristics through direct contact with bone marrow ...